The presence of neuroblastoma-specific mRNA in the cellular compartment of blood and bone marrow, such as PHOX2B, TH and CHRNA3, has been shown to correlate with outcome, enabling response monitoring in patients with high-risk disease [6,7,8,9]. The gene discussed is PHOX2B; the disease is neuroblastoma.